Spirulina and ankylosing spondylitis: IL-17, TNF-α, enthesitis, and biologic interactions

The immunopathology of AS

HLA-B27 and ER stress: HLA-B27 is positive in ~90% of AS patients. HLA-B27 homodimers misfold in the endoplasmic reticulum, triggering unfolded protein response (UPR) and IL-23 production by macrophages and dendritic cells. IL-23 drives IL-17A production from Th17 cells, innate-like lymphocytes, and γδ T cells at entheses and bowel wall.
Enthesis biology: The enthesis (tendon/ligament–bone insertion) in AS is the primary inflammatory target. Enthesitis involves resident macrophage activation, neutrophil recruitment, and neutrophil NOX2 respiratory burst generating superoxide. Superoxide drives NF-κB activation in fibroblasts and osteoblasts, amplifying IL-6, IL-8, and RANKL — promoting osteoclast activation and eventually paradoxical new bone formation (syndesmophytes).
Where spirulina acts: Phycocyanobilin inhibits NOX2 in neutrophils and macrophages, reducing the oxidative burst at entheses. Phycocyanobilin also suppresses NF-κB activation, reducing IL-6, IL-8, and downstream RANKL signalling. These actions do not replace biologic therapy in active AS but are complementary mechanisms operating at the same inflammatory site.

Active AS produces sustained IL-6 elevation, driving hepcidin production and functional iron restriction — the same mechanism as anaemia of chronic disease in RA and IBD. Ferritin is an acute-phase reactant: it is often elevated in active AS even when iron stores are genuinely depleted.
Use transferrin saturation (<20%) and reticulocyte haemoglobin content rather than ferritin alone to assess true iron status in active AS. Spirulina iron is modest (2–4 mg/5 g non-haem) but contributes to dietary iron intake alongside a vitamin C source.
The anti-inflammatory effect of biologics on IL-6/hepcidin often improves anaemia in active AS without additional iron supplementation. Spirulina’s modest iron is not expected to be sufficient for significant anaemia correction in active disease — full-dose oral or IV iron is required if anaemia is confirmed.

TNF inhibitors are monoclonal antibodies or fusion proteins — not metabolised by hepatic CYP enzymes. There is no pharmacokinetic interaction with spirulina.
The relevant concern is spirulina’s NK cell stimulation and IL-12 induction. TNF inhibitors reduce immunosurveillance — this is why they increase infection risk. Adding NK stimulation from spirulina is directionally opposed to this effect and is not expected to cause harm; it is not expected to negate biologic efficacy. The combination is used by some AS patients without documented adverse outcomes, but discuss with your rheumatologist.

IL-17 inhibitors are monoclonal antibodies; no CYP pharmacokinetic interaction with spirulina.
IL-17 is directly involved in mucosal immunity against Candida. IL-17 inhibitors increase mucocutaneous candidiasis risk. Spirulina’s NK activation adds innate antifungal immunity that may be partially complementary to this gap. No clinical data on this interaction. Discuss with rheumatologist.

NSAIDs remain backbone treatment in AS for pain and possibly slowing radiographic progression. No pharmacokinetic interaction between spirulina and NSAIDs. Both have anti-inflammatory effects operating via different mechanisms (COX-1/2 inhibition vs NOX2/NF-κB).
GI tolerance: NSAIDs cause gastric irritation; spirulina polysaccharides have mild gastroprotective mucosal effects in some data. Net effect on NSAID GI tolerance is not documented but no increased irritation risk.

Methotrexate is used in peripheral AS and psoriatic arthritis overlap. Spirulina’s folate (~25–40 µg/5 g) provides a very small contribution to folate intake but is well below the 5 mg folinic acid supplement dose used to protect against methotrexate toxicity. No documented interaction.

AS is strongly associated with gut dysbiosis and subclinical ileitis (>50% of AS patients have microscopic ileal inflammation on biopsy). The gut-enthesis axis is mechanistically supported: intestinal IL-23 drives circulating ILC3s and Th17 cells that migrate to entheses.
Spirulina polysaccharides support Lactobacillus and Bifidobacterium growth (prebiotic activity), which may reduce gut dysbiosis and intestinal IL-23 signalling. This is speculative in AS context but mechanistically coherent.

Active AS on biologic therapy: discuss NK stimulation with rheumatologist before starting; in practice many patients on TNF inhibitors use spirulina without documented adverse effects
Active AS on NSAIDs only: 3–5 g/day; no interaction concerns; anti-inflammatory mechanisms are complementary
Iron status: use transferrin saturation, not ferritin alone, in active disease before supplementing iron
Vitamin C with spirulina to optimise non-haem iron absorption (particularly important given hepcidin-mediated restriction in active AS)
No phytoestrogenic activity; no interaction with sulfasalazine or hydroxychloroquine if used for peripheral joint involvement